BIBA Publishing
Huntleigh releases Dopplex ankle and toe pressure kit
The kit comprises the company's DMX Doppler, probes and accessories to aid the vascular, diabetic or lymphatic specialist with the assessment of arterial disease and neuropathy.
Cook Medical issues global recall of select lots of central venous...
Cook Medical has initiated a voluntary recall of 360 specific lots of single lumen central venous catheters and pressure monitoring sets and trays due to catheter tip fracture and/or separation. Globally, 17,827 devices are subject to this recall.
Huntleigh releases Dopplex DMX digital vascular Doppler
Huntleigh has launched the Dopplex DMX digital vascular Doppler. According to a company release, this Doppler combines audio clarity and a visual representation of waveforms with high performance probe sensitivity.
Zilver Vena self-expanding venous stent preliminary European results announced
At procedure, Zilver Vena stent placement resulted in a more than two-fold improvement in the vessel minimum lumen diameter. Based on available follow-up data, stent placement has corresponded to improved clinical symptoms.
SEATTLE II results show no intracranial haemorrhage or no death among...
The study concluded that treatment with ultrasound-facilitated catheter-directed low-dose thrombolysis for acute pulmonary embolism improves right heart function, reduces blood clot size, and decreases pulmonary hypertension in patients with intermediate to high risk pulmonary embolism.
Biolas introduces VariClose in Europe
After the European launch in April 2015, Biolas has introduced the VariClose Vein Sealing Systems in the European market for the treatment of varicose veins.
NICE recommends once-daily Lixiana (edoxaban) for the treatment and prevention of...
NICE has issued a Final Appraisal Determination (FAD) for Lixiana (edoxaban) for the treatment and prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults.
CryoLife receives expanded indication for BioGlue in Japan
BioGlue is now indicated for adhesion and support of haemostasis for aortotomy closure sites, suture/anastomosis sites (including aortic dissection and anastomosis sites with a prosthetic graft), and suture sites on the heart.
Cyanoacrylate embolisation agent non-inferior to radiofrequency ablation for incompetent great saphenous...
Twelve-month results from the VeClose trial have demonstrated cyanoacrylate adhesive (CAE) is non-inferior to radiofrequency ablation (RFA) for the treatment of incompetent great saphenous veins.
VenaSeal demonstrates 96.8% closure rate in the treatment of incompetent greater...
The 12-month closure rates for Medtronic's VenaSeal closure system are comparable to those achieved using radiofrequency ablation.
Surgical Specialties announces Medicare approval of transitional pass-through reimbursement for BioSentry...
The decision provides supplemental reimbursement to US hospitals for the new medical device with the potential to improve outcomes for patients undergoing a percutaneous transthoracic lung biopsy.
NICE publishes final guidance on the use of Eliquis (apixaban) to...
As part of a 90-day implementation plan, the NHS now has three months for apixaban to be made available to patients in England and Wales whose doctors believe it is a clinically appropriate treatment for them.
Use of vena cava filter does not reduce risk of recurrent...
Observational studies show a sharp increase in the placement of inferior vena cava filters over the past three decades, including their use as add-on therapy to anticoagulant therapy in patients presenting with a blood clot.
FDA approves closure system to permanently treat varicose veins
The Medtronic VenaSeal system is intended for patients with symptomatic superficial varicose veins of the legs.
Endobronchial forceps effective in retrieval of tip-embedded inferior vena cava filters
Leaving the devices in place risks filter fracture or symptoms from penetration of filter components outside of the vein into adjacent structures, increased risk of new blood clots in the legs, and other complications.
Veniti announces first US patients enrolled in VIRTUS trial
Veniti has enrolled the first US patients in the VIRTUS trial of the Venti Vici venous stent system, with four procedures performed at two sites.
FDA approves Cardinal Health MynxGrip Vascular Closure Device for venous indication
Cardinal Health has announced that its MynxGrip Vascular Closure Device recently received Food and Drug Administration (FDA) approval for use to close femoral veins. The MynxGrip device is now indicated for use to seal 5F, 6F and 7F femoral arterial and femoral venous access sites.
First patient enrolled in US study of Novate’s Sentry IVC filter
Novate Medical has announced that Souheil Saddekni, professor of Vascular and Interventional Radiology at the University of Alabama, Birmingham, USA, has enrolled the first patient in the SENTRY IDE study.
EJVES introduces new online journal
The Editors of the European Journal of Vascular and Endovascular Surgery have announced the introduction of a new Open Access, online journal to run alongside the existing journal.
FDA clears EkoSonic endovascular system
Ekos Corporation has announced that the US Food and Drug Administration (FDA) has cleared the EkoSonic endovascular system for the ultrasound facilitated, controlled and selective infusion of physician-specified fluids, including thrombolytics, into the vasculature for the treatment of pulmonary embolism.
Vascular News Issue 60 – November 2013 – Digital Edition
Highlights: -Vascular surgery societies refuse to endorse TASC III -ESVS announces bankruptcy of annual meeting organiser -3D contrast-enhanced ultrasound potentially better at detecting endoleaks -Profile: Lowell Kabnick
Vascular News Issue 60 – November 2013 – USA Digital Edition
Highlights: -Vascular surgery societies refuse to endorse TASC III -ESVS announces bankruptcy of annual meeting organiser -3D contrast-enhanced ultrasound potentially better at detecting endoleaks -Profile: Lowell Kabnick
Cook Medical opens new Innovation Centre in Ireland
The company's Limerick site develops peripheral vascular, gastroenterology and urology devices for global distribution, and the Innovation Centre is a dedicated space enabling the company to collaborate closely with physicians.
First commercial implantations of Crux vena cava filter announced
The double helical, symmetrical design of the Crux device helps prevent filter tilt, as the helical design self-centres automatically within the vena cava upon deployment. The device offers the Bi-Trieval option of retrieval via either the jugular or femoral vein.
Vascular News Issue 59 – September 2013 – USA Digital Edition
Highlights: -Inadequate sealing is top reason for endograft explant -"Aortic debranching safe and durable up to five years" -A unified voice for vascular surgery in Latin America by Alberto Munoz -Profile: Thomas Zeller.
Vascular News Issue 59 – September 2013 – Digital Edition
Highlights: -Inadequate sealing is top reason for endograft explant -"Aortic debranching safe and durable up to five years" -A unified voice for vascular surgery in Latin America by Alberto Munoz -Profile: Thomas Zeller.
Intermittent pneumatic compression could reduce risk of deep vein thrombosis after...
A multicentre study has confirmed the effectiveness of intermittent pneumatic compression systems in reducing the incidence of deep vein thrombosis following a stroke. According to a press release, incidence could be reduced by 29%.
BTG announces acquisition of EKOS
EKOS owns, manufactures and distributes the EkoSonic Endovascular System (EkoSonic), an interventional device that uses a locoregional approach in the treatment of severe blood clots.
Endurant shows durable outcomes at three years
In the US study with the device, there was 100% freedom from aneurysm-related mortality, 0% post-implant aneurysm rupture, 0% graft migration and 0% conversion to open repair for the 107 patients followed to three years.
Vascular News Issue 58 – June 2013 – USA Digital Edition
Highlights: - Management of type II endoleak divides the experts at CX35 - Intermittent claudication: Lack of funding for supervised exercise programmes remains a global problem - First-in-man implantation of left subclavian artery branched TEVAR device
Vascular News Issue 58 – June 2013 – Digital Edition
Highlights:
- Management of type II endoleak divides the experts at CX35
- Intermittent claudication: Lack of funding for supervised exercise programmes remains a global problem
- First-in-man implantation of left subclavian artery branched TEVAR device
CT is the best imaging modality for deep vein thrombosis
Gerard O'Sullivan, Galway, Ireland, CX35 delegates that computed tomography pulmonary angiography (CTPA) and CT venography are his preferred imaging modalities.
CX Daily News Tuesday 9 April 2013
Highlights:
-Clinical need drives intraoperative imaging to the next level
-CX ilegx Collaboration embraces Electronic Endovascular Education
-A completely percutaneous closure approach is feasible in most cases
-Hands-on training and learning at the CX Office-Based Vein Practice Course
CX Daily News Monday 8 April 2013
Highlights:
-Experts sharply divided on type II endoleak challenge
-Cordis launches Smart Flex stent at CX35
-Developments in imaging go under the scanner at CX35
-CX St George's Vascular Access Course explores new technologies and research
CX Daily News Sunday 7 April 2013
Highlights:
-Intermittent claudication - Lack of funding for supervised exercise programmes is a global problem
-Latin America comes to CX
-Latest data from peripheral trials presented at CX35
-Substantial improvement in functional status with bioresorbable scaffold at 30 days
Vascular News Charing Cross Edition 2013
Highlights:
-What to expect from CX35
-Advanced imaging technology at the heart of CX35
-CX35 provides record number of educational opportunities
-Summary of Vascular News and Interventional News’ profiles 2012
Vascular News Issue 57 – January 2013 – USA Digital Edition
Highlights:-Initial experience of total endovascular arch aneurysm exclusion is "encouraging"-Stroke associated with a threefold increased future mortality in CREST-Advances in drug therapy for the treatment of thrombophlebitis and pulmonary embolism-Profile: Peter Gloviczki
Vascular News Issue 57 – January 2013 – Digital Edition
Highlights:-Initial experience of total endovascular arch aneurysm exclusion is "encouraging"-Stroke associated with a threefold increased future mortality in CREST-Advances in drug therapy for the treatment of thrombophlebitis and pulmonary embolism-Profile: Peter Gloviczki
Vascular News Issue 56 – November 2012 – Digital version USA
Highlights:
-Early follow-up shows promising results with bioabsorbable stent in the superficial femoral artery
-Is the Cotavance withdrawal in the USA a setback for drug-eluting balloons?
-ACST-2 first results indicate carotid revascularisation is becoming safer
-Profile: Piergiorgio Cao
Vascular News Issue 56 – November 2012 – Digital version
Highlights:
-Early follow-up shows promising results with bioabsorbable stent in the superficial femoral artery
-Is the Cotavance withdrawal in the USA a setback for drug-eluting balloons?
-ACST-2 first results indicate carotid revascularisation is becoming safer
-Profile: Piergiorgio Cao
Vascular News Issue 55 – September 2012 – Digital version USA
Highlights:-Intensive endovascular simulation training improves performance-Stem cell mobilisation shows trend in improving amputation rate in critical limb ischaemia-Chimney and periscope grafts safe and effective to facilitate EVAR or hybrid procedures for complex aortic aneurysms-Profile: Frank Lederle
Vascular News Issue 55 – September 2012 – Digital version
Highlights:-Intensive endovascular simulation training improves performance-Stem cell mobilisation shows trend in improving amputation rate in critical limb ischaemia-Chimney and periscope grafts safe and effective to facilitate EVAR or hybrid procedures for complex aortic aneurysms-Profile: Frank Lederle
Blood clots unlikely to be prevented by statins
Despite previous studies suggesting the contrary, statins may not prevent venous thrombo-embolism in adults, according to a large analysis by international researchers published recently in PLOS Medicine.
EKOS announces two more pulmonary embolism clinical studies
SEATTLE I and II are intended to further establish the safety and efficacy of ultrasound accelerated thrombolysis for treatment of pulmonary embolism.
Vascular surgery recognised as independent specialty in the UK
On 16 March 2012, the Parliament gave statutory approval recognising vascular surgery as a specialty independent from general surgery in the United Kingdom.
FDA and industry reach agreement in principle on medical device user...
The recommendations would authorise the FDA to collect US$595 million in user fees over five years, plus adjustments for inflation.
Physician Payments Sunshine Act regulatory guidance released in the USA
The Centers for Medicare and Medicaid Services (CMS) has issued proposed regulatory guidance for implementing the Physician Payments Sunshine Act developed by senators Herb Kohl and Chuck Grassley in the USA.
FDA issues two draft guidance documents to facilitate investigational medical device...
The US Food and Drug Administration FDA has issued a draft guidance aimed at fostering early-stage development of medical devices within the United States.
ESVS and EJVES celebrate 25 years of support for high quality...
Simon Parvin, consultant vascular surgeon, secretary general of The European Society for Vascular Surgery (ESVS) speaks on the history and major achievements of the ESVS.
A new low-dose alteplase to restore patency to occluded central venous...
Boehringer Ingelheim launched Actilyse Cathflo 2mg, a low-dose vial of the thrombolytic alteplase. Actilyse Cathflo 2mg is used to restore the patency of central venous access devices, including those used in haemodialysis.
New statement offers advice on treating dangerous, deep blood clots
The American Heart Association's scientific statement offers advice for identifying and treating people with massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension.
Vascular Solutions launches the Disposable Vein Hook
This novel device is intended for single patient use for the treatment of superficial varicose veins and varicosities associated with superficial reflux and incompetence of the great saphenous vein in the lower limbs.
EkoSonic receives CE mark to treat massive and sub-massive pulmonary embolism
The EkoSonic system, originally designed to dissolve blood clots in arms and legs, is the new alternative for the treatment of pulmonary embolism; until now, drugs were the only approved treatment.
DUET compares standard catheter-directed vs. ultrasound-accelerated thrombolysis
The DUET study, a randomised trial conducted to compare standard catheter-directed thrombolysis vs. ultrasound-accelerated thrombolysis in The Netherlands, has begun enrolment of its 60 thrombo-embolic infra-inguinal disease patients.
National Innovation Centre cites VNUS Closure procedure as select innovative technology
Minimally invasive treatment for varicose veins to be showcased at National Health Service EXPO
NHS National Innovation Centre cites VNUS Closure Procedure as “select innovative...
UK NHS National Innovation Centre identifies the VNUS Closure procedure as a "select innovative technology"
Venous day at CX 31
Dr Nick Morrison will open the CX Venous Day, on Tuesday 7 April, with a talk on foam sclerotherapy.
Management of deep vein thrombosis
DVT, other than that triggered by trauma or surgery, is now considered to be a chronic disease with a high risk of recurrence.
VNUS ClosureFAST results ‘very encouraging’
"ClosureFAST provides the ability to deliver high-energy dosage to obtain a successful treatment ..."
‘Rapid lysis’ technique could potentially change DVT treatment
Results at the Society of Interventional Radiology's 32nd Annual Scientific Meeting, in Seattle, WA, Dr Mark J Garcia.
Cook’s Z-Trak Plus Introduction System gains European approval
Z-Trak Plus Introduction System provides trackability and manoeuvrability for precise, controllable device orientation and deployment of the company's thoracic aneurysm stent graft
Remon ImPressure device utilised in first patients
"...This monitor will be easy for my patients to use at home, and is expected to give early warning of the need for treatment, avoiding hospitalisation and deterioration in the patient's condition."
VALOR II and VIRTUE to evaluate Valiant system
"The Valiant stent graft has quickly become the most widely used thoracic graft outside the United States..."
Boost for stenting in the SFA
The results from three studies revealed that stenting is a safe and effective treatment option for treating SFA lesions
12-year UK SAT results justifies surveillance policy
Presentation of results from 2 studies at this years annual meeting of the Vascular Society.
EVEM data highlights continued European growth of EVAR procedures
Stephen Greenhalgh, London, UK, presented data in November 2006 at the Carpe Diem Vascular meeting in Barcelona, Spain.
A tribute to Professor Edmondo Malan
Professor Roger Greenhalgh pays a fitting tribute to Professor Edmondo Malan at this year's IVEC 2006 meeting.
What is the best treatment for varicose veins?
A fascinating exchange of views at this year's VEITHsymposium, three experts on venous disease presented data on various treatments for varicose veins.
The prevention of venous ulcers
ESVS meeting, delegates were honoured to have a distinguished panel before them.
UK Vein Conference 2006
The conference featured talks and demonstrations from the experts in the field from UK, Europe and USA
VNUS established UK subsidiary
New UK subsidiary will begin sales of VNUS Closure products directly in the UK market 2007
Venous Registry launched at EVF meeting
Venous Registry is to produce an annual publication similar to the vascular and adult cardiac surgical reports
Stents may have future in venous disease
Study plans to enrol up to 50 patients with chronic deep venous insufficiency and venous ulcers (present for at least six months)
A comprehensive portfolio of techniques for varicose veins
Dangers of leaving the decision in primary care
Vein Hopes
Vascular News highlights the latest research developments for the treatment of varicose veins
Promising results for superficial femoral artery stenting
Results presented by Dr Martin Schillinger
Transatlantic carotid trial to focus asymptomatics
Optimal treatment strategy for patients with asymptomatic carotid disease
Superficial venous surgery reduces venous ulcer recurrence
The ESCHAR study results show that superficial venous surgery reduces venous ulcer recurrence.
Endovenous laser vs RF: Long-term results
Comparing the long term results of endovenous laser and endovenous RFA Therapy